![[刘小婷]](https://staticloudone.ablesci.com/avatar/u/b901337a524b2f8aa312b155bd115e5c.png?v=5b0f)
Lv7
4090 积分 2022-09-21 加入
Izalontamab brengitecan (Iza-bren; BL-B01D1), a first-in-class EGFR-HER3 bispecific antibody–drug conjugate, for patients with EGFR-mutated NSCLC: pooled analysis of phase I and phase II trials
5天前
已完结
BL-B01D1, a first-in-class EGFR–HER3 bispecific antibody–drug conjugate, in patients with locally advanced or metastatic solid tumours: a first-in-human, open-label, multicentre, phase 1 study
5天前
已完结
Becotatug vedotin, MRG003, in previously treated recurrent or metastatic nasopharyngeal carcinoma: A multicenter, single-arm, phase IIa trial
5天前
已完结
Clinical relevance of EGFR- and KRAS-status in colorectal cancer patients treated with monoclonal antibodies directed against the EGFR
5天前
已完结
Novel colorectal cancer screening methods — opportunities and challenges
5天前
已完结
Wild-type RAS signaling is an essential therapeutic target in RAS -mutated cancers
18天前
已完结
Immortalized fibroblasts from NF-κB RelA knockout mice show phenotypic heterogeneity and maintain increased sensitivity to tumor necrosis factor α after transformation by v-Ras
1个月前
已完结
“The RAS Dam Has Broken”
1个月前
已完结
Discovery and Characterization of RP03707: A Highly Potent and Selective KRASG12D PROTAC
1个月前
已完结
Potential of enhancer of zeste homolog 2 inhibitors for the treatment of SWI/SNF mutant cancers and tumor microenvironment modulation
1个月前
已完结
皖公网安备34019202002308
